Novel products for the treatment of haemophiliaWritten by Paul Giangrande
Chair, EHC Medical Advisory Group, Oxford, UK
Paul Giangrande is the chair of the EHC Medical Advisory Group (MAG). He has been in this position since 2013.
In 2015, Prof Giangande retired from his position as consultant haematologist at Oxford University Hospitals NHS Trust (UK), where he was also the director of the Oxford Haemophilia Centre.
Prof Giangrande qualified in medicine from the University of Manchester (UK) in 1979, after previously doing a First-Class Bachelor of Science (BSc) degree in pharmacology. After obtaining postgraduate qualifications in both adult and paediatric medicine, he trained in haematology in various major hospitals in London. He obtained a research doctorate in 1991 for his work at the Royal Free Hospital in London (UK) on immunological aspects of haemophilia treatment. He subsequently worked in Italy at the Milan Haemophilia Centre with Professor PM Mannucci between 1989 and 1990, before being appointed to his position in Oxford in 1991.